Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

January 29, 2021

Conditions
Social Anxiety DisorderPerformance Anxiety
Interventions
DRUG

BHV-0223

35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.

DRUG

Placebo

a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.

Trial Locations (1)

06508

Connecticut Mental Health Center, New Haven

Sponsors
All Listed Sponsors
collaborator

Biohaven Pharmaceuticals, Inc.

INDUSTRY

lead

Yale University

OTHER